Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zynlonta (loncastuximab tesirine-lpyl) is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• In the ASCT-eligible group, the pooled 1-year progression-free survival (PFS) rate for CAR T-cell therapy was 0.40 (95% CI, 0.15 to 0.65), compared to 0.34 (95% CI, 0.30 to 0.37) for chemotherapy followed by ASCT, with no significant difference observed.
• In the ASCT-ineligible group, the pooled 1-year PFS rate for CAR T-cell therapy was 0.40 (95% CI, 0.35 to 0.46), and this therapy showed significantly better outcomes compared to chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and tafasitamab showed no different efficacy compared to CAR T-cell therapy after adjusting for prior treatments.
• No subgroup analyses based on factors such as age, gender, or comorbid conditions were reported within the ASCT-eligible and ASCT-ineligible groups.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.